Preventive stenting in acute myocardial infarction

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiovascular Research

Background:

• Current guidelines recommend intervention solely on the culprit vessel in ST-segment elevation myocardial infarction (STEMI) with multivessel coronary disease.
• The PRAMI trial suggests potential benefits of preventive percutaneous coronary intervention (PCI) for non-culprit lesions during primary PCI for STEMI.

Purpose of the Study:

• To review the pathophysiology of non-culprit vessel plaque in STEMI.
• To summarize existing literature on multivessel PCI in STEMI.
• To discuss the implications of the PRAMI trial and future research directions.

Main Methods:

• Literature review and synthesis of existing data.
• Analysis of the PRAMI trial findings in the context of previous studies.
• Discussion of STEMI pathophysiology and its impact on non-culprit lesions.

Main Results:

• The PRAMI trial demonstrated reduced rates of cardiac death, myocardial infarction, and refractory angina with preventive PCI of significant non-culprit lesions.
• Existing data on multivessel PCI during STEMI are largely retrospective and have historically cautioned against the practice.
• Uncertainty remains regarding the long-term impact of treating non-culprit lesions and the comparison between simultaneous and staged PCI approaches.

Conclusions:

• Advances in PCI may allow for safer consideration of multivessel intervention in STEMI.
• The PRAMI trial provides compelling evidence for preventive PCI, challenging previous guidelines.
• Further clinical trials are warranted to establish optimal strategies for managing multivessel disease in STEMI, including staged PCI comparisons.